Table 2. Cox proportional hazards regression models of variables associated with survival outcomes.

|  |  |  |  |
| --- | --- | --- | --- |
|  | Recurrence-free survival  | Cancer-specific survival | Overall survival |
|  | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis |
|  | HR | 95% CI | *P* value | HR | 95% CI | *P* value | HR | 95% CI | *P* value | HR | 95% CI | *P* value | HR | 95% CI | *P* value | HR | 95% CI | *P* value |
| Age (years) | 1.01  | 0.98-1.03 | 0.655  |  |  |  | 1.01  | 0.99-1.04 | 0.317  |  |  |  | 1.03  | 1.01-1.06 | 0.012  | 1.01  | 0.99-1.04 | 0.324  |
| Body mass index (kg/m2) | 1.11  | 0.96-1.27 | 0.149  | 1.04 | 0.90-1.20 | 0.601  | 1.10  | 0.96-1.27 | 0.186  |  |  |  | 1.11  | 0.98-1.27 | 0.105  | 1.05  | 0.92-1.20 | 0.481  |
| Serum creatinine (μmol/l) | 1.00  | 0.98-1.02 | 0.841  |  |  |  | 1.00  | 0.98-1.02 | 0.674  |  |  |  | 1.00  | 0.99-1.02 | 0.711  |  |  |  |
| Tumor stage | 1.25  | 1.00-1.56 | 0.049  | 1.00  | 0.77-1.20 | 0.970  | 1.24  | 0.99-1.56 | 0.065  | 1.02 | 0.78-1.32 | 0.886 | 1.38  |  1.12-1.71 | 0.003  | 1.19  | 0.94-1.52 | 0.154  |
| Histology (non-squamous vs. squamous) | 1.83  | 1.08-3.11 | 0.026  | 1.48 | 0.84-2.62 | 0.179  | 2.00  | 1.17-2.42 | 0.011  | 1.45  | 0.80-2.61 | 0.218  | 1.70  | 1.02-2.85 | 0.042  | 1.21  | 0.69-2.11 | 0.506  |
| Tumor differentiation (G3 vs. G1-2) | 2.16  | 1.26-3.72 | 0.005  | 2.87 | 1.58-5.21 | 0.001  | 2.79  | 1.65-4.72 | <0.0001 | 4.19 | 2.30-7.64 | <0.0001 | 2.37  | 1.43-3.92 | 0.001  | 3.27  | 1.88-5.70 | <0.0001 |
| Tumor size (≥4cm vs. <4cm) | 2.64  | 1.57- 4.45 | <0.0001 | 1.51 | 0.85-2.68 | 0.159 | 2.75  | 1.61-4.71 | <0.0001 | 1.55  | 0.85-2.81 | 0.152  | 2.53  | 1.57-4.10 | <0.0001 | 1.31  | 0.76-2.25 | 0.332  |
| Deep stromal invasion (yes vs. no) | 2.59  | 1.40-4.81 | 0.003  | 0.94 | 0.48-1.84 | 0.852 | 2.67  | 1.43-4.96 | 0.002  | 0.87 | 0.44-1.75 | 0.706 | 3.06  | 1.69-5.54 | <0.0001 | 1.25  | 0.65-2.41 | 0.499  |
| LVSI (yes vs. no) | 2.45  | 1.50-4.02 | <0.0001 | 1.25 | 0.74-2.12 | 0.405 | 2.32  | 1.41-3.82 | 0.001  | 1.04 | 0.60-1.80 | 0.896 | 1.94  | 1.24-3.02 | 0.004  | 0.98  | 0.60-1.59 | 0.928  |
| Positive margins (yes vs. no) | 10.02  | 5.57-18.06 | <0.0001 | 3.21  |  1.65-6.24 | 0.001 | 11.00  | 6.04-20.08 | <0.0001 | 4.13  | 2.11-8.08 | <0.0001 | 8.85  | 4.82- 16.26 | <0.0001 | 2.77  | 1.40-5.45 | 0.003  |
| Positive nodes (yes vs. no) | 8.08  | 4.65- 14.06 | <0.0001 | 6.53 | 3.59-12.22 | <0.0001 | 7.80  | 4.45-13.64 | <0.0001 | 7.16  | 3.73-13.75 | <0.0001 | 5.23  | 3.28-8.35 | <0.0001 | 4.01  | 2.31-6.97 | <0.0001 |
| Positive parametrium (yes vs. no) | 8.89  | 4.74-16.51 | <0.0001 | 2.77 | 1.39-5.51 | 0.004  | 10.98  | 5.93-20.32 | <0.0001 | 3.04  | 1.54-5.98 | 0.001  | 8.85  | 4.82- 16.26 | <0.0001 | 3.49  | 1.80-6.77 | <0.0001 |
| Diabetes mellitus |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  No | Reference | Reference | Reference | Reference | Reference | Reference | Reference | Reference | Reference | Reference | Reference | Reference | Reference | Reference | Reference | Reference | Reference | Reference |
|  HbA1c < 7% | 2.75  | 1.38-5.49 | 0.004  | 1.47 | 0.67-3.20 | 0.336  | 2.83 | 1.37-5.88 | 0.005  | 1.44  | 0.63-3.31 | 0.386  | 2.79  | 1.40-5.55 | 0.004  | 1.77  | 0.82-3.80 | 0.144  |
|  HbA1c ≥ 7% | 5.87  | 3.54-9.74 | <0.0001 | 3.45 | 1.92-6.20 | <0.0001 | 6.65 | 3.97-11.16 | <0.0001 | 3.95  | 2.17-7.18 | <0.0001 | 7.38  |  4.61-11.80 | <0.0001 | 4.80  | 2.81-8.20 | <0.0001 |
| Hypertension (yes vs. no) | 1.60  | 0.99-2.60 | 0.056 | 1.52 | 0.91-2.53 | 0.107 | 1.67 | 1.02-2.76 | 0.043  | 1.64 | 0.98-2.75 | 0.060  | 1.56  | 0.98-2.48 | 0.061  | 1.46  | 0.90-2.38 | 0.127  |
| Cardiovascular disease (yes vs. no) | 1.14  | 0.49-2.63 | 0.758 |  |  |  | 0.96 | 0.38-2.37 | 0.923  |  |  |  | 0.97  | 0.42-2.22 | 0.941  |  |  |  |
| Metformin (yes vs. no) | 1.36  | 0.75-2.47 | 0.316 |  |  |  | 1.53 | 0.84-2.80 | 0.166  |  |  |  | 1.36  | 0.77-2.38 | 0.287  |  |  |  |

Abbreviation:CI, confidence interval; HR, hazard ratio; HbA1c, hemoglobin A1c; LVSI, lymphatic vascular space involvement;